Minimally Invasive Procedures in the Diagnosis and Treatment of Localized Prostate Cancer: an Interventional Radiologist’s Perspective

Yaniv Avital1,2* · Jurgen J. Fütterer1 · Alexei Cherniavsky2 · Joyce G. R. Bomers1

Accepted: 30 April 2022 / Published online: 7 June 2022
© The Author(s) 2022

Abstract

Purpose of Review  Minimal invasive procedures, including targeted biopsy (TB) and focal therapy (FT), are increasingly used in diagnosis and treatment of localized prostate cancer. Here, we review the current role of these procedures, from a perspective of an interventional radiologist.

Recent Findings  TB is an established part of current guidelines for diagnosis of PCa. Several modalities of FT are gaining prevalence in recent years, as a tissue-preserving alternative for definitive treatment of localized PCa. FT is currently at early research stages, offered to selected patients in clinical trials settings.

Summary  TB and FT are minimally invasive procedures used by multidisciplinary teams for diagnosis and treatment of localized PCa.

Keywords  Localized prostate carcinoma · Focal therapy · Partial gland ablation · Targeted biopsy · Interventional radiology · Multi-parametric MRI

Introduction

Prostate cancer (PCa) is the second most common cancer in men. It represents a major health burden in developed countries with a growing proportion of elderly men in the population and widespread PSA screening programs [1•, 2•]. To that end, multiparametric magnetic resonance imaging (mpMRI) plays a central role in the diagnosis of clinically significant PCa (CsPCa) by determining PI-RADS classification and obtaining targeted biopsy (TB). mpMRI has also been shown to reduce the number of unnecessary biopsies in biopsy-naive patients and improves the accuracy of tumor grading and volume determinations in patients which had a prior negative systematic 12-core TRUS biopsy (SB) [3, 4, 5•]. TB are now integrated in the updated guidelines of the European Association of Urology (EAU) for PCa [1•] and are planned and executed by multidisciplinary specialist teams which include (interventional) radiologists, urologists, and/or oncologists.

Robust current data has demonstrated that for low- and intermediate-risk localized PCa, none of the definitive treatments (i.e., radical prostatectomy (RP) and radiotherapy (RT)) has proved to be superior to active surveillance (AS) in terms of overall and PCa-specific 10-year survival [1•, 6••]. Low-risk PCa is associated with a very favorable prognosis and can therefore be managed by AS in order to reduce overtreatment and defer curative treatment to the point of evident disease progression. However, AS is associated with psychological burden on patients and an increased rate of disease progression and re-classification [1•, 6••]. Conversely, definitive treatments (e.g., surgery) are associated with treatment-related morbidity including erectile, urinary,
and bowel dysfunctions, contributing to decreased quality of life. In recent years, these key concerns have led to the development of focal therapy (FT), as a less invasive, less morbid way for patients with low- and intermediate-risk disease to be treated. FT is a tissue-preserving strategy which aims to improve the benefit-to-risk ratio by decreasing disease progression related to AS, while reducing the morbidity related to whole gland treatment. Interventional radiologists (IRs) use image-based maneuvers to deliver several available forms of FT.

FT, including cryotherapy and high-intensity focused ultrasound (HIFU), are currently in early research stages according to the Idea, Development, Exploration, Assessment, Long-term study (IDEAL) recommendations [7••]. It is therefore recommended that FT be implemented only within clinical trial settings or well-designed prospective cohort studies [1•]. Nevertheless, in the past 5 years, the number of such studies has doubled compared to the previous two decades [7••], reflecting the current interest in minimal invasive procedures for treatment of localized PCa. Therefore, the purpose of this review article is to describe the minimal invasive procedures currently used for diagnosis and treatment of localized PCa, from an IRs perspective.

PCa Diagnosis

TB based on mpMRI information increases the detection rate of csPCa and reduces the detection rate of clinically insignificant prostate cancer [4, 5•, 8, 9]. TB is therefore strongly recommended by current guidelines for patients with a PI-RADS ≥ 3 mpMRI, either in combination with SB for biopsy-naive patients, or as a sole examination for patients which have had a prior negative biopsy [1•, 10]. As a result, the number of patients undergoing TB is steadily increasing [11], inevitably increasing the role of s IRs in the diagnostic pathway. TB can be performed by either MRI or sonographic guidance. MRI guidance, i.e., in-bore MRI-TB (MRGB), employs real-time MR images to direct the biopsy needle towards the index lesion. It enables direct MR imaging confirmation of accurately targeting the index lesion. The procedure is commonly performed in a transrectal approach using a robotic assistance device to achieve higher accuracy and shorter procedure time compared to the manual approach [12]. However, a transperineal in-bore approach is also performed. Sonographic guidance is performed by either software-assisted fusion of MRI images with real-time ultrasound images, i.e., fusion MRI-TB (F-TB) or cognitive registration of the MRI images by the ultrasound operator performing the biopsy, i.e., cognitive MRI-TB (C-TB). Sonographically guided TB does not require MRI-compatible equipment and reduces MR-scanner time, increasing its cost effectiveness compared with MRGB and making it more accessible [13].

In the recent randomized controlled FUTURE trial, no significant difference was found in the diagnostic accuracy of the three biopsy techniques (MRGB, F-TB, C-TB) in a prior negative biopsy patient cohort [14]. A recent prospective study showed similar results in biopsy-naive patients [15]. Watts et al. reported in a meta-analysis of no significant difference in detection rates of csPCa between F-TB and C-TB [16]. Costa et al. reported a higher diagnostic accuracy for MRGB compared with F-TB combined with SB in a population with both biopsy-naive and prior negative biopsy patients [17, 18]. A recent collaborative review on the subject concluded that there is no clear consensus on the optimal targeting approach and that detection rates were associated with practitioner experience and patient selection criteria [19].

In a recent meta-analysis, an alternative transperineal approach was associated with lower infection rates compared to systematic transrectal approach and better access to the apex and anterior zones [20]. Transperineal biopsy is therefore strongly recommended in the new EAU guidelines [10].

Recently, a risk stratification strategy was proposed to enable a limited biopsy protocol of the peripheral zone for selected patients with an exclusively peripheral lesion [21]. The authors suggested that when mpMRI demonstrate a suspicious peripheral zone lesion without a suspicious lesion in the transition zone, the following combined SB and TB can be limited to the peripheral zone, omitting SB of the transition zone, thereby reducing biopsy-related morbidity without a significant change in detection rate of csPCa.

Wetterauer et al. suggested in a large retrospective analysis that MRI-targeted biopsies lead to overestimation of tumor volume compared with traditional volume assessment using systematic biopsies, deeming ineligibility of suitable patients for AS. The authors proposed a new algorithm to assess eligibility for FT which is based on a broader risk stratifying composite [11].

FT Strategy

FT is a minimally invasive approach designed to selectively target and destroy the most aggressive cancer foci, referred to as the index lesion. Although the disease is often multifocal, the targeted index lesion is a major prognostic determinant for disease progression and risk of metastases [22]. An expert panel for the relevant standardized nomenclature agreed that all lesions which are biopsy-confirmed, MRI-visible, and intermediate grade (i.e., Gleason grade group
(GGG) 2/Gleason 3 + 4 = 7) should be targets for FT. They did not agree as to whether the index lesion is defined solely by being the largest lesion and whether GGG1 lesions can be defined as index lesions [23].

FT is intended to spare adjacent critical structures such as neurovascular bundle, rectum, bladder, and urethra, which are often compromised as a result of definitive treatments. It is defined as an image-guided ablation of the index lesion as opposed to partial gland ablation which refers to image-guided regional ablation based on anatomic boundaries. Partial gland ablation templates include hemiablation, quadrant ablation, hockey-stick ablation, and subtotal ablation (Fig. 1) [23]. Templates are set according to lesion-specific parameters such as location, volume, and extension. For FT, a minimum of 1-cm margin around the index lesion is recommended to avoid residual disease [24, 25]. A recent study reported that the size of a lesion on mpMRI is typically underestimated compared with its actual pathological size, especially in smaller lesions with lower PIRADS scores. The authors suggested that a larger ablation margin is required for such lesions [26].

**Patient Selection**

Focal therapy was initially offered as an alternative to active surveillance in patients with low-risk PCa. In recent years, it has also been advocated for patients with intermediate-risk localized PCa, as an alternative for radical treatment. A recent Delphi consensus from a multidisciplinary, multi-institutional, international expert panel suggested that FT can be offered to selected patients who are discontinuing AS [26]. The panel agreed that patients with a solitary Gleason 3 + 4 lesion (GGG 2) are suitable for FT, while patients with multiple clinically significant lesions (≥ GGG 2) which are not located anteriorly in the prostate are not suitable for FT.

---

**Fig. 1** FT and partial gland ablative template. Focal therapy: Focused ablation of an image-visible index lesion. Partial gland ablation: destruction of all prostate tissue within an anatomical ablation zone, aiming to preserve at least one neurovascular bundle. Ablation templates include as follows: Quadrant ablation — a quadrant of the prostate tissue; Hemi-ablation — a lateralized hemisphere of the prostate or the anterior half of the prostate; Hockey stick ablation — prostate tissue within a lateralized hemisphere plus anterior contralateral region; Subtotal ablation — most of the prostate tissue with preservation of a posterior lateral region (unilaterally or bilaterally)
According to the updated European Association of Urology (EAU) guidelines [1•], FT may be offered within a clinical trial setting to patients with low- and intermediate-risk disease, defined as PSA < 10 ng/mL and GS < 7 and PSA 10–20 ng/mL or GS 7, respectively. FT should not be offered to patients with high-risk disease. Nazziri et al. reported that 38.5% of biopsy-proven lesions identified on mpMRI were eligible for FT, based on eligibility criteria of intermediate-risk lesion (GS 4 + 3) with or without other low-risk foci [27, 28]. Selection of suitable patients for FT relies on pragmatic factors and individual risk stratification [29, 30]. The visibility of the lesion on mpMRI is sufficient for image guided FT in 72–88% of patients [31]. Patients which are not suitable for image-guided FT may be offered partial gland ablation based on histopathological mapping [8]. Several available calculators, such as the European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSPC-RC3), are used for risk stratifying assessment. mpMRI parameters, such as PI-RADS category, zonal location of the index lesion, and prostate volume, are considered, as well as a combined analysis of clinical parameters such as PSA level, DRE, and patient’s age [29, 30, 32, 33]. Intra-ductal or cribriform histopathology are associated with higher progression rates, therefore considered less suitable for FT [8].

**Focal Ablative Treatments**

Focal ablative therapies use one of several available high energy sources to damage the index lesion. Because of the need for real-time image guidance, focal ablative therapies are often delivered by IRs. According to their main ablation mechanism, they can be categorized into thermal and non-thermal energy sources. Irreversible electroporation (IRE), photodynamic therapy (PDT), and focal brachytherapy use non-thermal sources of energy. High-intensity focused ultrasound (HIFU), transurethral ultrasound ablation (TULSA), cryotherapy, focal laser ablation (FLA, Fig. 2), and radio-frequency ablation (RFA) are thermal sources of energy. Thermal-based therapies cause a progressive gradient of thermal dispersion around the targeted lesion [24]. A recent systematic review compared the oncologic and functional outcomes between thermal and non-thermal energy sources, reporting individual advantages and disadvantages of each FT modality [34].

**Fig. 2** A 68-year-old male presenting with an elevated PSA level of 5 ng/mL was diagnosed with prostate cancer in the right peripheral zone in the midportion of his prostate, Gleason score of 3 + 4 = 7 (ISUP 2).

a T2-weighted MR image of the lesion before treatment.

b Contrast enhanced image directly at the end of the focal laser ablation procedure, showing lack of enhancement at the ablation bed. At 1-year follow-up after treatment, the patient’s PSA level dropped to 2.2 ng/mL and the following MRI images confirmed no evidence of residual or recurrent tumor at the treatment area: c Perfusion weighted color MR image, showing lack of perfusion in the treated area. d T2-weighted MR image, showing complete focal atrophy of the treated area.
HIFU, PDT, and IRE are currently in more advanced research stages and will be briefly described in this section.

HIFU is performed under ultrasound or MRI guidance in an external or transrectal approach. The phased array transducer generates high-intensity ultrasound (usually greater than 500 W/cm²), causing focal coagulative necrosis, in a process known as sonification. MRI offers real-time quantitative thermometry maps and the ability to precisely visualize the post-procedural ablated volume using dynamic contrast-enhanced images. HIFU can be performed as a stand-alone treatment or following transurethral resection of the prostate (TURP), intended to reduce the risk of urinary retention and improve treatment efficacy by decreasing prostate volume. Due to its limited penetration depth, HIFU is less suitable for very large prostates or for anterior zone lesions [13]. A recent study reported short term significantly decreased efficacy of HIFU treatment of the anterior hemi-gland compared with HIFU treatment of the posterior gland [35]. HIFU is the most studied method of FT to date, including in ongoing studies. Most HIFU-related studies are at IDEAL stage 2, two studies are at IDEAL stage 3, and one large retrospective study is at IDEAL stage 4 [7••]. In terms of oncological outcome, studies report a median of 8% disease free in the treated area with a median follow-up of 12 months. In terms of functional outcomes, no significant changes in urinary continence and erectile function were found. Yap et al. reported a transient postoperative erectile dysfunction with no significant difference after 1 year [36]. Initial results from the PART RCT show significant advantage for HIFU over RP in terms of erectile function and continence [37].

IRE ablation delivers high voltage low energy electric current using electro-needles positioned in the perineum under TRUS guidance. It relies on a non-thermal mechanism, inducing cell death by a series of brief direct-current electrical pulses which disrupts cellular homeostasis leading to apoptosis. IRE represents 13% of FT studies, with most studies being at IDEAL stage 2 and one study in IDEAL stage 3. In terms of oncological outcome, studies report a median of 8.5% recurrence of CaP in the treated area with a median follow-up of 12 months. Functional outcomes showed no significant change in urinary continence but a significant decrease in erectile function.

Vascular-targeted PDT uses a photosensitizing agent, such as bacteriochlorophyll derivative padoporfin, which is activated by light to generate reactive oxygen species, causing local thrombosis and focal necrosis. Photodynamic therapy represents 10% of FT studies, with most studies at IDEAL stage 2 and two studies at IDEAL stage 3 (based on a single trial). In terms of oncological outcome, studies report a median of 90% disease free in the treated area. The larger RCT [38] reported a median follow-up of 24 months and showed favorable oncological outcomes compared to AS. In terms of functional outcomes, no significant changes in urinary continence or erectile dysfunction were found.

Complications of Focal Ablative Treatments

A recent review summarized the relevant evidence on the complications related to FT and their management [24]. Transient minor adverse events are common and include urinary tract infection, dysuria, hematuria, and acute urinary retention. Incontinence is rare (0–5%) and transient. Baseline erectile function and the ablation volume are the most important predictors of postoperative erectile dysfunction which occurs in 0–46% of the cases.

Contrarily to the positive functional outcomes following FT, the ProtecT study group reported significant and persistent increase in the rates of urinary incontinence and erectile dysfunction following RP (55% and 95% respectively at 6 months), nocturia following RT, and erectile dysfunction and bowel dysfunction following RT (88% and 5% respectively at 6 months) [6••].

Fiared et al. recently proposed implementing an in-depth evaluation of the sexual side effects following FT, using semiconstructed interviews in addition to validated questionnaires. Their aim in this future study is to capture the more subtle sexual function changes associated with the different FT modalities, in order to enhance decision-making process for patients who prioritize preserving specific aspects of their sexual function [39].

When FT was compared to whole-gland therapy using the same treatment modality (HIFU and cryoablation), a significant association was found between the treatment area and related toxicity [2]. The location of the ablation target affects the frequency and type of complications. Proximity to the neurovascular bundle with capsule contact may impact erectile function while foci closer to urethra or bladder neck are associated with a higher rate of postoperative irritative and obstructive lower urinary tract symptoms (LUTS) [24]. Schmidt et al. reported that almost two-thirds of the patients receiving HIFU treatment did not experience any adverse events. They demonstrated a higher complication rate at the anterior base (50%) and with association to longer distance between the HIFU probe and the index lesion secondary to increased tissue involvement [40].

Salvage FT after RT has a much higher toxicity profile than focal therapy in the primary setting [41]. However, a recent review evaluated the role of several FT modalities as salvage therapy in the setting of local recurrence after primary RT. They reported promising oncological results in terms of biochemical control with an acceptable toxicity profile [42].
**Endovascular Treatments**

Endovascular treatments aim to induce prostate ischemia by bland or chemotherapeutic embolization of one or both prostatic arteries, i.e., prostatic artery embolization (PAE) and chemoembolization (PACE). Vascular territory-based therapy is performed by IRs only. As opposed to focal ablative therapy, it enables treatment in difficult-to-access regions including anterior and apical zones, and lowers the risk of metachronous CsPCa in the remaining prostatic tissue, as lower grade lesions in the treated area are also exposed to treatment induced ischemia [43]. A retrospective analysis of tumor-related pathologic angiographic findings in patients with PCa reported arteriovenous fistula (AVF) in 10% of cases, representing a potential risk of nontarget embolization [44]. A recent case series evaluated the feasibility of PAE in 10 patients with low-risk PCa under AS [43]. Unilateral PAE was performed using 300–500-μm microspheres aiming for locoregional ischemia in the affected prostatic lobe. The authors reported promising short-term oncological and functional effectiveness and suggested that PAE may be offered as “reinforced AS” strategy. A previous study regarding PAE as a palliative treatment for advanced stage PCa reported significant complications and equivocal oncological results when aiming to achieve cytoreduction using 100-μm microspheres for proximal and bilateral PAE [45].

Pisco et al. performed bilateral PACE in 16 patients with localized PCa, most of which had a low-risk disease [46]. They reported a short-term significant reduction in PSA, followed by a 37.5% relapse rate at 12 months, an acceptable functional outcome, and a significant reduction in prostate volume. Recently, a preclinical study in animal models aimed to evaluate as a proof of concept the feasibility and efficacy of docetaxel-loaded bead PACE in canines with advanced stage metastatic prostate cancer [47]. They reported a low systemic toxicity profile and up to 70% decrease in prostate volume.

PAE and PACE represent a future therapeutic option for localized PCa, unique for IRs, yet these therapies are currently in early experimental stages (IDEAL 1) and their place as a viable option for FT is not clear yet.

**Follow-up After FT**

The Société Internationale d’Urologie-International Consultation on Urologic Diseases (SIU-ICUD) recommends performing the follow-up mpMRI and prostate biopsy between 3 and 6 months following FT [48]. Serial PSA studies and mpMRI have been suggested as alternatives for post-ablative disease control [49]. However, to date, there is lack of an established evidence-based protocol for the optimal timing and technique for post-ablative follow-up [48, 50, 51]. A recent clinical cohort reported that 6 months following partial gland cryo-ablation, PSA and mpMRI were poor predictors of disease persistence in the treatment bed. The authors suggested that considering the low incidence of short-term disease persistence following partial gland cryo-ablation, early follow-up biopsy may be deferred up to 2 years in appropriate patients [50]. A recent large multi-center retrospective study reported that the percentage of PSA reduction following HIFU for low- and intermediate-risk localized PCa may be used as a follow-up strategy since it can predict the likelihood of additional FT (30%) or definitive treatment (13%) [51]. Conversely, Felker et al. reported that mpMRI at 6 and 12 months after FLA for low and intermediate csPCa was highly accurate for predicting the presence of residual csPCa and significantly outperformed serial PSA measurements [52]. Recently, an International Multidisciplinary Consensus panel proposed a uniform postprocedural surveillance regimen after FT [23]. They recommended PSA measurement every 3 months in the first year and every 6 months thereafter; mpMRI at 6 and 18 months after treatment; TB combined with systematic 12 core TRUS biopsy at 6–12 months after treatment and functional outcome assessment at 3–6 months after treatment and until stability is reached.

**Evidence Base for FT and Recommendations for Future Research**

Several forms of FT are being investigated in recent years for their functional and oncological efficacies. In a recent systematic review by Hopstaken et al. [7••], the accumulated evidence base for FT was evaluated according to IDEAL recommendations. They examined 72 recent and 43 ongoing studies, all aiming to assess the functional and oncological outcomes of eight different energy sources of FT. Most studies were found to be prospective development studies in IDEAL stage 2a and 2b, with only five studies regarding PDT, HIFU, and IRE in more advanced research stages, i.e., IDEAL stages 3–4. Ongoing trials demonstrated similar trends. The authors concluded that even though FT has been studied extensively and at an increasing rate over the past half-decade, the majority of studies remain in an early research stage. They suggested that more high-quality evidence should be acquired before FT can become a standard treatment.

Similar results and appropriate recommendations for clinical practice were outlined in a SR by the association of Urology (EAU) Prostate Cancer Guideline Panel as part of the guideline update for 2020 [53••]. In this systematic review, the panel evaluated the current evidence
base for FT and compared its feasibility as a therapeutic alternative to the established standard management options, i.e., definitive treatments and AS. The panel concluded that the present collective evidence is limited with insufficient reliable evidence to support FT as a clinical strategy for localized PCa. They recommended that FT should not influence clinical decision-making nor be implemented in routine clinical practice and that it should be restricted to clinical studies solely. The panel determined that regarding low-risk disease, FT is likely to encourage overtreatment and cause adverse events without providing certain long-term oncological benefits, and that these patients should preferably be managed by improving contemporary AS protocols and strategy. Furthermore, they suggested that the future of FT lies in the intermediate-risk disease setting or for patients on AS protocol with evident disease progression. Either way, in order to gain high-quality evidence needed to endorse FT as a feasible option, the panel recommended that high level evidence including future clinical trials, RCTs, and prospective long-term trials should be conducted, and that collaborative databases and online registries platforms be encouraged. Finally, the panel reported on at least eight ongoing prospective studies that may yield moderate to high certainty data by 2027.

**Conclusion**

This review provides an overview of the current minimally invasive procedures used for diagnosis of PCa and treatment of localized csPCa, from the perspective of an IR. Minimal invasive procedures are gaining preference due to expedited recovery and low complication rates; new and improved treatment modalities are constantly emerging. Interventional oncology is a fast-growing discipline in clinical oncology with an expected increase of global tumor ablation market by 12% during 2021–2026 [54]. In the era of mpMRI-based TB and FT, interventional radiologists are an important part of the multidisciplinary teams treating PCa, providing real-time image interpretation skills and experience.

TB has become an established, integral part of the current diagnostic mpMRI and MRI-directed biopsy pathway of PCa, incorporated into the current diagnostic guidelines. FT is an evolving and promising alternative for definitive treatments, currently at early research stages. Several modalities of FT are offered in clinical trials settings, gaining medium- and long-term evidence base of their oncological efficacy.

**Declarations**

**Conflict of Interest** The authors declare no competing interests.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Papers of particular interest, published recently, have been highlighted as:
- Of importance
- Of major importance

1. • EAU guidelines. Edn. presented at the EAU Annual Congress Milan 2021. 2021.8. Integration of current data regarding diagnosis of PCa and treatment of localized PCa into the current EAU guidelines.
2. Borges RC, et al. Impact of focal versus whole gland ablation for prostate cancer on sexual function and urinary continence. J Urol. 2021;205(1):129–36. https://doi.org/10.1097/JU.0000000000001327.
3. Padhani AR, et al. PI-RADS Steering Committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology. 2019;292(2):464–74. https://doi.org/10.1148/radiol.2019182946.
4. Rouvière O, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100–9. https://doi.org/10.1016/S1470-2045(18)30569-2.
5. Kasivisvanathan V, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77. https://doi.org/10.1056/NEJMoai1801993. (A study that demonstrated the importance of performing MRI before prostate biopsy and the added value of TB vs SB alone for detecting csPCa in biopsy naive patients. This study added to the body of evidence leading to a shift in the diagnostic pathway of PCa and integration of TB in the updated guidelines of the European Association of Urology.)
6. • Neal DE, et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol. 2020;77(3):320–30. https://doi.org/10.1016/j.eururo.2019.10.030. (Fundamental RCT demonstrating that for low- and intermediate-risk localized PCa,
none of the definitive treatments (i.e., radical prostatectomy (RP) and radiotherapy (RT)) has proved to be superior to active surveillance (AS) in terms of overall and PCa-specific 10-year survival. This trial led to an enhanced development of FT as a middle way for patients with low- and intermediate-risk PCa.)

7. Hopstaken JS, Bomers JGR, Sedelaar MJF, Valerio M, Füterer JJ, Rovers MM. An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol. 2021. https://doi.org/10.1016/j.euro.2021.08.005. (A systematic review examining the accumulated evidence base for FT according to IDEAL recommendations, showing that the majority of recent studies regarding FT remain in an early research stage, suggesting that more high-quality evidence should be acquired before FT can become a standard treatment.)

8. Ahmed HU, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017;389(10071):815–22. https://doi.org/10.1016/S0140-6736(16)32401-1.

9. Drost F-JH, et al. Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis. Eur Urol. 2020;77(1):78–94. https://doi.org/10.1016/j.euro.2019.06.023.

10. Mottet N, et al. EAU-ENM-ESTRO-ESUR-SIog guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62. https://doi.org/10.1016/j.euro.2020.09.042.

11. Wetterauer C et al. Indication for active surveillance in the era of MRI-targeted prostate biopsies. Urologia Internationalis. 2021;1–7. https://doi.org/10.1159/000517300.

12. Sathianathen NJ, et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis. Eur Urol. 2020;78(3):402–14. https://doi.org/10.1016/j.euro.2020.03.048.

13. van Luijtfelaar A, Füterer JJ, Bomers JG. Minimally invasive magnetic resonance image-guided prostate interventions. Br J Radiol. 2021. https://doi.org/10.1259/bjr/20210698.

14. Weesela O, et al. The FUTURE trial: a multicenter randomised controlled trial on biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol. 2019;75(4):582–90. https://doi.org/10.1016/j.euro.2018.11.040.

15. Krüger-Stokke B, Bertilsson H, Langstreen S, Sjøbakk TAE, Baten TF, Selmès KM. Multiparametric prostate MRI in biopsy-naïve men: a prospective evaluation of performance and biopsy strategies. Front Oncol. 2021;11. https://doi.org/10.3389/fonc.2021.745657.

16. Watts KL, et al. Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer. Urol Oncol Semin Original Investig. 2020;38(9):734.e19-734.e25. https://doi.org/10.1016/j.urolonc.2020.03.020.

17. Costa DN, et al. Magnetic resonance imaging-guided in-bore and magnetic resonance imaging-transrectal ultrasound fusion targeted prostate biopsies: an adjusted comparison of clinically significant prostate cancer detection rate. Eur Urol Oncol. 2019;2(4):397–404. https://doi.org/10.1016/j.euo.2018.08.022.

18. Costa DN, et al. Gleason grade group concordance between preoperative targeted biopsy and radical prostatectomy histopathologic analysis: a comparison between in-bore MRI-guided and MRI–transrectal US fusion prostate biopsies. Radiol Imaging Cancer. 2021;3(2):e200123. https://doi.org/10.1148/ryan.2021200123.

19. Jager A, Vilanova JC, Michi M, Wijstra H, Odds J. The challenge of prostate biopsy guidance in the era of mpMRI detected lesion: ultrasound-guided versus in-bore biopsy. Br J Radiol. 2021;20210363. https://doi.org/10.1259/bjr/20210363.

20. Pradere B, et al. Nonantibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol. 2021;205(3):653–63. https://doi.org/10.1097/JU.0000000000001399.

21. Kachanov M, et al. Optimizing combined magnetic resonance imaging-targeted and systematic biopsy strategies: sparing the multiparametric magnetic resonance imaging-negative transitional zone in presence of exclusively peripheral multiparametric magnetic resonance imaging-suspect lesions. J Urol. 2021. https://doi.org/10.1097/JU.0000000000002248.

22. Nassiri N, et al. Focal therapy eligibility determined by magnetic resonance imaging-ultrasound fusion biopsy. J Urol. 2018;199(2):453–8. https://doi.org/10.1016/j.juro.2017.08.085.

23. Lebastchi AH, et al. Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus. Urol Eur. 2020;78(3):371–8. https://doi.org/10.1016/j.euro.2020.05.018.

24. Rakauskas A, et al. Focal therapy for prostate cancer: complications and their treatment. Front Surg. 2021.8: . https://doi.org/10.3389/fsurg.2021.696242.

25. Priester A, Elkhoury F, Vandel J, et al. Targeted prostate biopsy: cancer extends beyond the ROI! J Urol. 2018;199(4S):519–520.

26. Tan WP, et al. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: recommendations of an international Delphi consensus. Urol Oncol Semin Original Investig. 2021;39(11):781.e17-781.e24. https://doi.org/10.1016/j.urolonc.2021.01.027.

27. Mohler JL, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19–30. https://doi.org/10.6004/jnccn.2016.0004.

28. Jarow JP, Ahmed HU, Choyke PL, Taneja SS, Scardino PT. Partial gland ablation for prostate cancer: report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop. Urology. 2016;88:8–13. https://doi.org/10.1016/j.urology.2015.11.018.

29. Bui T-L, et al. Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI). Abdom Radiol. 2021;46(9):4388–400. https://doi.org/10.1007/s00261-021-03097-6.

30. Remmers S, Roobol MJ. Personalized strategies in population screening for prostate cancer. Int J Cancer. 2020;147(11):2977–87. https://doi.org/10.1002/ijc.33045.

31. Filson CP, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer. 2016;122(6):884–92. https://doi.org/10.1002/cncr.29874.

32. Falagario UG et al. Does multiparametric magnetic resonance of prostate outperform risk calculators in predicting prostate cancer in biopsy naïve patients? Front Oncol. 2021;11:10. https://doi.org/10.3389/fonc.2021.603384.

33. Alberts AR, et al. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European randomized study of screening for prostate cancer risk calculators. Eur Urol. 2019;75(2):310–8. https://doi.org/10.1016/j.euro.2018.07.031.

34. Fainberg JS, et al. A systematic review of outcomes after thermal and nonthermal partial prostate ablation. Prostate Int. 2021. https://doi.org/10.1016/j.pri.2021.04.001.
35. Huber PM, et al. Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World J Urol. 2021;39(4):1115–9. https://doi.org/10.1007/s00345-020-03297-7.

36. Yap T, et al. The effects of focal therapy for prostate cancer on sexual function: a combined analysis of three prospective trials. Eur Urol. 2016;69(5):844–51. https://doi.org/10.1016/j.eururo.2015.10.030.

37. Handy FC, et al. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility Assess. Health Technol Assess. 2018;22(32):1–96. https://doi.org/10.3310/hta22520.

38. Azzouzi A-R, et al. Padeliporin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(2):181–91. https://doi.org/10.1016/S1470-2045(16)30661-1.

39. Fiard G, Kelly D, Yap T, Emberton M. Detailing sexual outcomes after treatment of localised prostate cancer with focal therapy using various energy sources: protocol for a mixed-methods study. BMJ Open. 2020;10(12):e045500. https://doi.org/10.1136/bmjopen-2020-045500.

40. Schmid FA, et al. Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: safety outcomes and complications. Urol Oncol Semin Original Investig. 2020;38(4):225–30. https://doi.org/10.1016/j.urolonc.2019.09.001.

41. Khoo CC, et al. A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer. Transl Androl Urol. 2020;9(3):1535–45. https://doi.org/10.21037/tau.2019.08.21.

42. Mantica G, et al. Minimally invasive strategies for the treatment of prostate cancer recurrence after radiation therapy: a systematic review. Minerva Urol Nefrol. 2020;72(5). https://doi.org/10.23736/S0393-2249.20.03783-2.

43. Frandon J, et al. Early results of unilateral prostate arterial embolization as a focal therapy in patients with prostate cancer under active surveillance: cancer prostate embolisation, a pilot study. J Vasc Interv Radiol. 2021;32(2):247–55. https://doi.org/10.1016/j.jvir.2020.10.002.

44. Xu Z-W, Zhou C-G, Tian W, Shi H-B, Liu S. Angiographic findings relevant to prostatic arterial embolization in patients with prostate cancer. J Vasc Interv Radiol. 2020;31(6):899-902.e1. https://doi.org/10.1016/j.jvir.2020.02.012.

45. Mordasini L, et al. Prostatic arterial embolization in the treatment of localized prostate cancer: a bicentric prospective proof-of-concept study of 12 patients. J Vasc Interv Radiol. 2018;29(5):589–97. https://doi.org/10.1016/j.jvir.2018.01.766.

46. Pisco J, Bilhim T, Costa NV, Ribeiro MP, Fernandes L, Oliveira AG. Safety and efficacy of prostatic artery embolization for prostate cancer—initial experience. J Vasc Interv Radiol. 2018;29(3):298–305. https://doi.org/10.1016/j.jvir.2017.10.013.

47. Pellerin O, et al. Prostate artery chemomobilization in prostate cancer: a proof of concept study in spontaneous prostate cancer in a canine model. Diagn Interv Imaging. 2021. https://doi.org/10.1016/j.diii.2021.07.003.

48. Tay KJ, et al. Surveillance after prostate focal therapy. World J Urol. 2019;37(3):397–407. https://doi.org/10.1007/s00345-018-2363-y.

49. Dickinson L, et al. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity–focused ultrasound focal therapy for localized prostate cancer. Urol Oncol Semin Original Investig. 2017;35(1):30.e9-30.e15. https://doi.org/10.1016/j.urolonc.2016.07.015.

50. Wysock J, Becher E, Gogaj R, Velazquez N, Lepor H. Early oncological control following partial gland cryo-embolization: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. Prostate Cancer Prostatic Dis. 2021;24(1):114–9. https://doi.org/10.1038/s41391-020-0244-0.

51. Stabile A, et al. The role of percentage of prostate-specific antigen reduction after focal therapy using high-intensity focused ultrasound for primary localised prostate cancer. results from a large multi-institutional series. Eur Urol. 2020;78(2):155–60. https://doi.org/10.1016/j.eururo.2020.04.068.

52. Felker ER, et al. Utility of multiparametric MRI for predicting residual clinically significant prostate cancer after focal laser ablation. Am J Roentgenol. 2019;213(6):1253–8. https://doi.org/10.2214/AJR.19.21637.

53. Bates AS, et al. A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and recommendations for clinical practice and further research. European Urology Oncology. 2021;4(3):405–23. https://doi.org/10.1016/j.euo.2020.12.008. (Updated recommendation by the association of Urology (EAU) Prostate Cancer Guideline Panel, for clinical practice of FT. The panel recommended that FT should not influence clinical decision-making nor be implemented in routine clinical practice and that it should be restricted to clinical studies solely.)

54. ReportLinker. Tumor ablation market size, share & trends analysis report by technology, by treatment, by application, by region and segment forecasts, 2021 - 2028. https://www.reportlinker.com/p05867021?utm_source=GNW, Feb. 16, 2021.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.